Statements (71)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:biotechnology
|
| gptkbp:acquisition |
Acquired by the company in 2021
|
| gptkbp:business_model |
focused on drug development
|
| gptkbp:can_lead_to |
gptkb:CB-839
|
| gptkbp:clinical_trial |
gptkb:pharmaceuticals
ongoing published in scientific journals Phase 1 and Phase 2 defined for trials analyzed for efficacy designed to assess safety and efficacy in multiple cancer types targeting glutaminase |
| gptkbp:collaboration |
with academic institutions
|
| gptkbp:collaborations |
with biotech firms
with leading universities with leading cancer research centers |
| gptkbp:community_engagement |
involved in cancer awareness initiatives
|
| gptkbp:drug_candidates |
target specific cancer pathways
|
| gptkbp:drug_candidates_pipeline |
includes multiple investigational drugs
|
| gptkbp:drug_development_process |
follows rigorous standards
|
| gptkbp:drug_discovery |
utilizes innovative approaches
|
| gptkbp:financial_performance |
reported quarterly earnings
|
| gptkbp:focus |
cancer therapeutics
|
| gptkbp:focus_area |
tumor metabolism
|
| gptkbp:founded |
gptkb:2010
|
| gptkbp:founder |
gptkb:Susan_M._Molineaux
|
| gptkbp:funding |
secured from various sources
|
| gptkbp:future_plans |
to expand clinical trials
|
| gptkbp:governance |
adheres to best practices
|
| gptkbp:has_advisory_board |
composed of industry experts
|
| gptkbp:headquarters |
gptkb:San_Francisco,_California
|
| https://www.w3.org/2000/01/rdf-schema#label |
Calithera Biosciences
|
| gptkbp:initiatives |
focused on cancer metabolism
|
| gptkbp:instruction_set |
small molecule inhibitors
|
| gptkbp:investment |
various venture capital firms
built through transparency maintains communication with stakeholders raised significant funding regularly updates investors |
| gptkbp:investment_focus |
oncology market
|
| gptkbp:is_a_platform_for |
targeted therapies
|
| gptkbp:leadership |
experienced management team
|
| gptkbp:marketing_strategy |
to enhance shareholder value
to penetrate oncology market |
| gptkbp:mission |
to develop innovative therapies for cancer patients
|
| gptkbp:number_of_employees |
approximately 50
|
| gptkbp:partnership |
collaborated with various pharmaceutical companies
|
| gptkbp:partnerships |
enhance research capabilities
with research institutions with global pharmaceutical companies |
| gptkbp:patient_population |
targeted in clinical studies
|
| gptkbp:pipeline_development |
expanding therapeutic options
|
| gptkbp:product |
in development for various cancers
|
| gptkbp:publications |
contributed to cancer research literature
|
| gptkbp:regulatory_compliance |
gptkb:FDA
filed with health authorities |
| gptkbp:research |
published in peer-reviewed journals
|
| gptkbp:research_areas |
oncology
in various stages of development |
| gptkbp:research_focus |
metabolic pathways in cancer
cancer metabolism and treatment. on metabolic diseases |
| gptkbp:stock_exchange |
gptkb:NASDAQ
|
| gptkbp:strategic_goals |
advancing cancer therapies
|
| gptkbp:trade |
CALA
|
| gptkbp:treatment |
monitored in trials
|
| gptkbp:type_of_business |
managed by experienced professionals
|
| gptkbp:website |
www.calithera.com
|
| gptkbp:bfsParent |
gptkb:Incyte_Corporation
|
| gptkbp:bfsLayer |
5
|